Beamtree Holdings Valuation

Q: What is the Fair Price of BMT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BMT (A$0.25) is trading below our estimate of [[fair value]] (A$2.48)

Is BMT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BMT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BMT (A$0.25) is trading below our estimate of fair value (A$2.48)

Significantly Below Fair Value: BMT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMT?

Key metric: As BMT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BMT. This is calculated by dividing BMT's market cap by their current revenue.
What is BMT's PS Ratio?
PS Ratio	2.6x
Sales	AU$27.60m
Market Cap	AU$70.99m

BMT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	-14.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BMT's PS Ratio compare to its peers?

The above table shows the PS ratio for BMT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.9x
ALC Alcidion Group	2.3x	8.2%	AU$85.9m
M7T Mach7 Technologies	2.9x	18.1%	AU$84.4m
MDR MedAdvisor	1.3x	13.4%	AU$159.9m
PCK PainChek	17.2x	n/a	AU$45.8m
BMT Beamtree Holdings	2.6x	21.9%	AU$71.0m

Price-To-Sales vs Peers: BMT is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does BMT's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
MDR MedAdvisor	1.3x	13.4%	US$103.90m
DOC Doctor Care Anywhere Group	0.3x	6.3%	US$15.25m
IME ImExHS	0.7x	20.5%	US$11.86m
VFX Visionflex Group	1.7x	n/a	US$7.58m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BMT is good value based on its Price-To-Sales Ratio (2.6x) compared to the Global Healthcare Services industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is BMT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.6x
Fair PS Ratio	0.9x

Price-To-Sales vs Fair Ratio: BMT is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.5m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

-4.5%

33.3%

Cogstate

AU$166.4m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.96

-2.5%

-36.9%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

-22.2%

n/a